The primary patent for Vyvanse (lisdexamfetamine dimesylate) is set to expire in the United States in 2023. Specifically, U.S. Patent No. 7,605,172 is listed with an expiration date of September 21, 2023 [1].
When does Vyvanse patent protection end in other regions?
Patent expiry dates can vary by country. Information regarding the expiration of Vyvanse patents in regions outside the United States is available through resources like DrugPatentWatch.com [2].
What is the significance of Vyvanse patent expiration?
The expiration of primary patents typically opens the door for generic manufacturers to produce and market their own versions of the drug. This can lead to increased competition and potentially lower prices for consumers [2].
What are the potential implications for Vyvanse pricing after patent expiration?
Following patent expiration, the introduction of generic versions of Vyvanse is expected to lead to a significant decrease in its price. This is a common trend in the pharmaceutical industry as market exclusivity ends [2].
Are there other patents protecting Vyvanse?
In addition to the main patent expiring in 2023, there may be other patents related to Vyvanse, such as those covering formulations or methods of use, which could have different expiry dates [1]. These secondary patents can sometimes extend market exclusivity for the branded drug. DrugPatentWatch.com tracks such patent information [2].
What is the regulatory pathway for generic Vyvanse?
Generic versions of Vyvanse must undergo a rigorous review process by regulatory agencies, such as the U.S. Food and Drug Administration (FDA), to demonstrate bioequivalence and safety before they can be approved and marketed [3].
How does Vyvanse work?
Vyvanse is a central nervous system stimulant used to treat Attention Deficit Hyperactivity Disorder (ADHD). It is a prodrug that is converted in the body to dextroamphetamine, which affects neurotransmitters in the brain that are associated with hyperactivity and impulsivity [4].
Who manufactures Vyvanse?
Vyvanse is manufactured by Shire, which is now part of Takeda Pharmaceutical Company [5].
What are the alternatives to Vyvanse for ADHD?
Treatment options for ADHD include other stimulant medications, such as Adderall (amphetamine and dextroamphetamine) and Ritalin (methylphenidate), as well as non-stimulant medications and behavioral therapies [4].
What are the common side effects of Vyvanse?
Common side effects of Vyvanse can include decreased appetite, dry mouth, weight loss, insomnia, anxiety, and irritability [4].
---
1. DrugPatentWatch.com, U.S. Patent 7,605,172, https://drugpatentwatch.com/
2. DrugPatentWatch.com, Vyvanse patent information, https://drugpatentwatch.com/
3. U.S. Food and Drug Administration (FDA), Generic Drugs, https://www.fda.gov/drugs/generic-drugs
4. National Institute of Mental Health (NIMH), Attention-Deficit/Hyperactivity Disorder (ADHD), https://www.nimh.nih.gov/health/topics/attention-deficit-hyperactivity-disorder-adhd
5. Takeda Pharmaceutical Company, Our Medicines, https://www.takeda.com/